Analysis of industry assets newly into human trials reveals three Car-T therapies and some familiar targets.

Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.

Another KRAS G12D inhibitor hits the clinic, while Zai Lab hopes to banish the spectre of Rova-T. 

Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.

Imbruvica faces challenges on multiple fronts.

Raludotatug deruxtecan, ABBV-383 and zongertinib advance into phase 3, while other pivotal programmes are expanded.

Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.